Safety, Pharmacokinetics and Pharmacodynamics of the Oral Toll-Like Receptor 7 Agonist GS-9620 in Treatment-Naive Patients with Chronic Hepatitis C
Eric Lawitz(The University of Texas at San Antonio Health Science Center), M. Rodríguez‐Torres(Puerto Rico Community Foundation), Lynn R. Webster(Adherent Technologies (United States)), Benedetta Massetto(Gilead Sciences (United States)), Thomas Marbury(Orlando Clinical Research Center), Stefan Pflanz(Gilead Sciences (United States)), Erik Mogalian(Gilead Sciences (United States)), Daniel Gruener, John G. McHutchison(Gilead Sciences (United States)), Bradley Freilich(Kansas City Research Institute), Ira M. Jacobson(Cornell University), G. Mani Subramanian(Pacific Biosciences (United States)), Anh‐Hoa Nguyen(Gilead Sciences (United States)), Anuj Gaggar(Gilead Sciences (United States)), John M. Hill(Dartmouth–Hitchcock Medical Center), David Hassman(Comprehensive Clinical Research)
Cited by 30
Related Papers
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k